Application of a drug that reduces the iron content in the brain in the preparation of a drug for the treatment and / or prevention of neuropsychiatric disorders
Drugs like vadadustat and deferiprone reduce brain iron content to prevent and treat drug addiction, effectively reducing addictive behaviors with minimal side effects, addressing the lack of effective treatments for narcotic dependence.
Patent Information
- Application Number
- JP2024529160
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-02-17
- Filing Date
- 2022-05-26
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for drug addiction, particularly narcotic dependence, lack effective drugs that can prevent and treat addiction without causing addiction or severe side effects, and there is a need for new therapeutic strategies.
The application of drugs such as vadadustat and deferiprone, which reduce brain iron content, is used to prevent and treat drug addiction by reducing iron levels through oral administration or low iron content foods and beverages.
These drugs effectively reduce the formation of addictive behaviors by lowering iron content in the brain, demonstrating significant reduction in methamphetamine and morphine-induced conditioned place preference scores, with minimal side effects.
Smart Images

Figure 2024541385000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention belongs to the technical field of new uses of drugs, and in particular relates to the application of a drug that reduces iron content in the brain in the preparation of a drug for the treatment and / or prevention of neuropsychiatric disorders. [Background technology]
[0002] Narcotics refer to natural, semi-synthetic or synthetic substances that can cause dependence and stimulate or depress the central nervous system, resulting in hallucinations and impaired motor function, thinking, behavior, senses and mood. These include opium, morphine, heroin, cocaine, amphetamines, methamphetamine (Philopon), etc. Narcotic addiction, also known as drug dependence, drug abuse or substance use disorder, is a chronic relapsing brain disease characterized by compulsive drug use. Currently, drug trafficking is a problem in more than 170 countries and regions around the world, and drug consumption is a problem in more than 130 countries and regions. The number of people using drugs in the world exceeds 300 million, of which more than 35 million are addicted to drugs. The number of drug-related deaths has increased by 17.5% over the past decade. As of the end of 2020, China had a total of 1.801 million drug addicts, and 55.49 tons of drugs were seized in 2020. Drug addiction has become a serious social problem, and it places a huge medical and economic burden on our lives. Currently, drugs that clinically stop drug addiction are mainly opiate drugs represented by methadone and non-opiate drugs represented by clonidine. Opiate drugs can control symptoms better, but are addictive themselves, while non-opiate drugs are not addictive, but have obvious withdrawal symptoms and relatively large side effects. There are no particularly effective therapeutic drugs or clear treatment schemes for clinical drug / narcotic (especially new synthetic narcotic) addiction. Therefore, there is an urgent need to develop new drugs that can clinically prevent drug addiction, effectively control withdrawal symptoms, prevent relapse, and have almost no side effects.
[0003] Vadadustat (AKB-6548 / Vadadustat) is a new oral hypoxia-inducible factor prolyl hydroxylase inhibitor. Multiple clinical studies have demonstrated that vadadustat can significantly improve renal anemia and improve erythropoietin and hemoglobin levels in patients with chronic kidney disease. At the same time, it can regulate iron metabolism by reducing hepcidin and increasing transferrin without serious side effects, but its effect on narcotic or drug addiction or dependence has not yet been reported.
[0004] Deferiprone (CP20 / 3-hydroxy-1,2-dimethyl-4-(1H)-pyridone) is an iron chelating agent that can remove iron ions from ferritin and hemosiderin, and is used to treat acute iron poisoning and chronic iron accumulation diseases. Deferiprone is mainly used clinically to treat thalassemia patients with excessive iron load who are resistant or unwilling to accept existing chelating agent treatments. Many studies have reported that complexing excess iron can alleviate Parkinson's disease, senile dementia disease, and oxidative stress damage caused by iron overload, but its effect on narcotic or drug addiction or dependence has not yet been reported. Summary of the Invention [Problem to be solved by the invention]
[0005] In order to solve the above technical problems, the present invention provides an application of a drug that reduces the iron content in the brain in the preparation of a drug for treating and / or preventing neuropsychiatric disorders, and the drug that reduces the iron content in the brain is selected from vadadustat and deferiprone, which provides a drug for preventing and / or treating narcotic or drug addiction.The object of the present invention is to provide a strategy for preventing and treating narcotic or drug addiction by reducing the iron content in the brain with drugs or foods.
[0006] Considering the current lack of drugs for preventing and treating narcotic addiction in clinical practice, the present invention provides a new application of drugs or foods and beverages that reduce the iron content in the brain in preventing and treating drug or narcotic addiction or dependence. Specifically, the present invention provides an application of vadadustat, deferiprone and low-iron content foods and beverages in the preparation of drugs for preventing and treating narcotic or drug addiction or dependence. Currently, there are no relevant reports on preventing and treating narcotic or drug addiction or dependence by regulating the iron content in the brain. [Means for solving the problem]
[0007] The application of a drug that reduces the iron content in the brain in the preparation of a drug for preventing and / or treating mental disorders, which reduces the iron content in the brain, thereby having the effect of preventing and treating narcotic or drug addiction or dependence.
[0008] In one embodiment of the present invention, the mental disorder is a mental disorder caused by drugs, drug addiction or dependency.
[0009] In one embodiment of the invention, the narcotic drug is morphine or methamphetamine.
[0010] In one embodiment of the present invention, the drug is a hypoxia inducible factor prolyl hydroxylase inhibitor drug or an iron chelator drug.
[0011] In one embodiment of the present invention, the hypoxia inducible factor prolyl hydroxylase inhibitor drug is a compound of formula I or a pharma- ceutically acceptable salt thereof, the structure of which is: JPEG2024541385000002.jpg37170
[0012] In one embodiment of the present invention, the iron chelator drug is a compound represented by formula II or a pharma- ceutically acceptable salt thereof, the structure of which is: JPEG2024541385000003.jpg30170
[0013] In one embodiment of the invention, the pharma- ceutically acceptable salt comprises one or more of an inorganic acid salt, an organic acid salt, an alkylsulfonate, and an arylsulfonate.
[0014] In one embodiment of the present invention, the medicament for preventing and / or treating a mental disorder further comprises a pharma- ceutically acceptable carrier.
[0015] In one embodiment of the invention, the carrier is one or more selected from disintegrants, diluents, lubricants, adhesives, wetting agents, flavoring agents, suspending agents, surfactants and preservatives.
[0016] In one embodiment of the present invention, the dosage form of the drug for preventing and / or treating a mental disorder is a tablet, a capsule, a soft capsule, a granule, a pill, an oral liquid, an emulsion, an oral suspension, a dry extract, or an injection.
[0017] In one embodiment of the invention, the disintegrant is one or more selected from corn starch, potato starch, cross-linked polyvinylpyrrolidone, sodium starch glycolate, low-substituted hydroxypropylcellulose, croscarmellose sodium, carboxymethylcellulose, calcium carboxymethylcellulose, and alginic acid.
[0018] In one embodiment of the present invention, the lubricant is one or more selected from finely powdered silica gel, magnesium stearate, calcium stearate, stearic acid, talc and anhydrous silica gel.
[0019] In one embodiment of the invention, the adhesive is one or more selected from gum arabic, gelatin, dextrin, hydroxypropyl cellulose, methylcellulose and polyvinylpyrrolidone, the humectant is selected from sodium dodecyl sulfate, and the flavoring agent may be one or more of aspartame, stevioside, sucrose, maltitol and citric acid.
[0020] In one embodiment of the invention, the suspending agent is one or more selected from gum arabic, gelatin, methylcellulose, sodium carboxymethylcellulose, hydroxymethylcellulose and aluminum stearate gel, the surfactant is one or more selected from lecithin, sorbitan monooleate and glycerol monostearate, and the preservative is selected from methylparaben and / or propylparaben.
[0021] In the present invention, mice were fed a low-iron diet for 3 to 4 consecutive weeks to establish a mouse brain iron deficiency model, and then methamphetamine (2 mg / kg / day) was intraperitoneally injected into the mice, and methamphetamine conditioned place preference training was performed on the mice for 4 days to construct a drug addiction model. After the training, the preference score of the mice to stay on the methamphetamine side was measured, and it was shown that the preference score of the mice fed the low-iron diet to the methamphetamine side was significantly lower than that of the normal diet control group.
[0022] In the present invention, mice were fed a low-iron diet for 3 to 4 consecutive weeks to establish a mouse brain iron deficiency model, and then morphine (20 mg / kg / day) was intraperitoneally injected into the mice, and the mice were subjected to morphine-conditioned place preference training for 7 days to establish a drug addiction model. After the training, the preference score of the mice to stay on the morphine side was measured, and it was shown that the preference score of the mice fed the low-iron diet to the morphine side was significantly lower than that of the normal diet control group.
[0023] In the present invention, a drug addiction model was constructed by intraperitoneally injecting vadadustat (10 mg / kg / day) into mice every day, and then intraperitoneally injecting morphine (20 mg / kg / day) into the mice 6 hours later, and carrying out morphine conditioned place preference training for 7 days. After the training, the preference score of the mice to stay on the morphine side was measured, and it was shown that administration of vadadustat could significantly reduce the preference score of the mice to the morphine side.
[0024] In this study, we administered 1μL of 13mg / mL deferiprone to mice via stereotaxic catheter implantation in the brain (dorsal hippocampus), and 6 hours later, intraperitoneally injected morphine (20mg / kg / day) to the mice, and performed mouse morphine conditioned place preference training for 7 days to construct a drug addiction model. After the training, we measured the preference score of the mice to stay in the morphine side, and showed that deferiprone administration could significantly reduce the preference score of the mice to the morphine side.
[0025] Low iron content diet, deferiprone and vadadustat can all reduce the iron content in the brain and reduce the morphine and methamphetamine-induced conditioned place preference scores. Therefore, drugs or dietary formulations that reduce the iron content in the brain have a significant effect in the prevention and treatment of narcotic or drug addiction or dependence. Effect of the Invention
[0026] Compared with the prior art, the above technical solution of the present invention has the following advantages: (1) Considering the current lack of drugs to prevent and treat drug addiction clinically, existing drugs that reduce the iron content in the brain, such as vadadustat and deferiprone, can prevent the formation of addictive behaviors after administration of morphine and methamphetamine (e.g., low-iron content food and drink, 10 mg / kg / day vadadustat and deferiprone can significantly reduce morphine- and methamphetamine-induced conditioned place preference scores). (2) There are currently no drugs that can clinically prevent or treat new narcotic or drug addiction (e.g., methamphetamine) or dependence, and existing drugs that reduce iron content in the brain (e.g., vadadustat and deferiprone) are effective against methamphetamine addiction or dependence. (3) Clinically, opiate drugs such as methadone are addictive in themselves when used to treat opiate addiction (e.g., morphine, etc.), and may lead to drug dependence if used inappropriately. However, drugs that reduce existing iron content in the brain (e.g., vadadustat and deferiprone) are not addictive in themselves during the treatment of opiate addiction. (4) Clinically, non-opiate addiction treatment drugs such as clonidine can cause serious side effects when used for a long period of time. Existing iron-reducing drugs (such as vadadustat and deferiprone) are clinically well tolerated, have few side effects, and have not yet been reported to cause serious side effects when administered in reasonable doses. [Brief description of the drawings]
[0027] In order to make the contents of the present invention easier and clearer to understand, the present invention will be further described in detail below by means of specific embodiments of the present invention with reference to the drawings. [Figure 1] FIG. 1 is a graph showing the effect of the low-iron content food and drink according to the present invention on the iron content in the mouse brain. [Diagram 2] FIG. 2 is a graph showing the action and effect of a low-iron content food and drink on methamphetamine addiction in mice according to the present invention. [Diagram 3] FIG. 3 is a graph showing the action and effect of the low-iron content food and drink according to the present invention on morphine addiction in mice. [Figure 4] FIG. 4 is a graph showing the action and effect of vadadustat according to the present invention on morphine addiction. [Diagram 5] Figure 5 is a diagram showing the effect of deferiprone according to the present invention on morphine addiction. It should be understood that within the scope of the present invention, the above technical features of the present invention and the technical features specifically described below (e.g., in the Examples) can be combined with each other to form new or preferred technical solutions. Due to space limitations, detailed description is omitted here. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0028] The present invention will now be further described by specific examples with reference to the drawings so that those skilled in the art can better understand and practice the present invention, but the listed examples are not intended to limit the present invention.
[0029] Example 1: Regulatory effect of low-iron diet on iron content in mouse brain 1. Experimental materials The C57BL / 6J mice used in the present invention were purchased from Shanghai Silica Laboratory Animal Co., Ltd., and the low-iron diet used in the present invention was purchased from Jiangsu Cooperative Biotechnology Co., Ltd.
[0030] 2. Experimental Method 2.1 Method of administering drugs to mice Thirty-six male C57BL / 6J mice (8 weeks old, weighing 22-25g) were housed in an SPF-level animal room and were randomly divided into a normal diet control group (3 mice) and a low-iron diet control group (3 mice) after one week of adaptation. The mice in the low-iron diet group were continuously fed the low-iron diet for 3-4 weeks, while the mice in the normal diet group were fed normal diet.
[0031] 2.2 Measurement of iron content in mouse brain After raising the above mice for 3 to 4 weeks, the brain tissues of the mice were collected. The tissue samples were placed in a polytetrafluoroethylene nitrification inner tank, and 5 mL of nitric acid was added and soaked overnight. The inner lid was placed on the tank, the stainless steel jacket was tightened, and the tank was placed in a constant temperature dryer, and the tank was kept at 80°C for 2 hours, at 120°C for 2 hours, and at 160°C for 4 hours. The tank was naturally cooled to room temperature while still in the dryer, and after opening the tank, the tank was heated until the acidic solution was almost dry. The nitrification solution was sucked into a 25 mL measuring flask, and the inner tank and inner lid were washed three times with a small amount of nitric acid solution (1%). The washing solution was mixed into the measuring flask and the volume was adjusted to the scale with 1% nitric acid. The iron element content was measured by inductively coupled plasma mass spectrometry (ICP-MS).
[0032] 3. Experimental results As shown in Figure 1, the iron content in the striatum, hippocampus, and cortex tissues of the mice in the low-iron diet group was significantly reduced compared to the mice in the normal diet group, indicating that a low-iron diet may lead to a decrease in iron content in the brain.
[0033] Example 2: Effects of low-iron diet on methamphetamine addiction in mice 1. Experimental materials The C57BL / 6J mice used in the present invention were purchased from Shanghai Silica Laboratory Animal Co., Ltd., and the low-iron diet used in the present invention was purchased from Jiangsu Cooperative Biotechnology Co., Ltd.
[0034] 2. Experimental Method 2.1 Method of administering drugs to mice Thirty-six male C57BL / 6J mice (8 weeks old, weighing 22-25g) were housed in an SPF-level animal room and were adapted for one week before being randomly divided into a normal food and drink + saline control group (11 mice), a normal food and drink + methamphetamine group (13 mice), a low-iron content food and drink + saline control group (13 mice), and a low-iron content food and drink + methamphetamine group (12 mice). The mice in the low-iron content food and drink group were continuously fed a low-iron content diet for 3-4 weeks, and the mice in the normal food and drink group were fed a normal diet. The mice in the control group were intraperitoneally injected with saline, and the mice in the methamphetamine group were intraperitoneally injected with methamphetamine (2mg / kg / day). Injections were performed for four consecutive days.
[0035] 2.2 Mouse conditioned place preference experiment scores A conditioned place preference box (experimental apparatus) manufactured by Shanghai Jilin Software Technology Co., Ltd. was used as the behavioral training and detection apparatus. The experimental apparatus was divided into two boxes, a drug-containing box (black box) and a drug-free box (white box) (the two boxes were sealable and could be connected to each other). On the first day, the mice were placed in the experimental apparatus (connected state) and allowed to move freely for 900 seconds, and the activity time of the mice in the drug-containing box was recorded and analyzed as a baseline value. On the second day, drug addiction training was conducted, and the mice were administered medication according to the grouping requirements, and then restrained in the drug-containing box (sealed state) and trained for a total of 60 minutes per day for 4 days. After the training, on the sixth day, the mice were placed in the experimental apparatus and allowed to move freely for 900 seconds (connected state), and the activity time of the mice in the drug-containing box was recorded and analyzed. The difference between the activity time of the mice in the drug-containing box on the sixth day and the activity time of the mice in the drug-containing box on the first day (baseline) was used as the preference score.
[0036] 3. Experimental results As shown in Figure 2, there was a significant difference in preference scores between the normal food and drink + saline control group and the normal food and drink + methamphetamine group, indicating that a 2 mg / kg / day methamphetamine addiction model was successfully established. There was a significant difference in preference scores between the normal food and drink + methamphetamine group and the low-iron food and drink + methamphetamine group, indicating that the low iron content in the brain due to the low-iron food and drink has an effect on methamphetamine addiction.
[0037] Example 3: Effect of low iron content food and drink on morphine addiction in mice 1. Experimental materials The C57BL / 6J mice used in the present invention were purchased from Shanghai Silica Laboratory Animal Co., Ltd., and the low-iron diet used in the present invention was purchased from Jiangsu Cooperative Biotechnology Co., Ltd.
[0038] 2. Experimental Method 2.1 Method of administering drugs to mice Thirty-six male C57BL / 6J mice (8 weeks old, weighing 22-25g) were housed in an SPF-level animal room and were acclimated for one week before being randomly divided into a normal food and drink + saline control group (10 mice), a normal food and drink + morphine group (10 mice), a low-iron content food and drink + saline control group (8 mice), and a low-iron content food and drink + morphine group (9 mice). The mice in the low-iron content food and drink group were continuously fed a low-iron content diet for 3-4 weeks, and the mice in the normal food and drink group were fed a normal diet. The mice in the control group were intraperitoneally injected with saline, and the mice in the morphine group were intraperitoneally injected with morphine (20mg / kg / day). Injections were performed for 7 consecutive days.
[0039] 2.2 Mouse conditioned place preference experiment scores A conditioned place preference box (experimental apparatus) manufactured by Shanghai Jilin Software Technology Co., Ltd. was used as the behavioral training and detection apparatus. The experimental apparatus was divided into two boxes, a drug-containing box (black box) and a drug-free box (white box) (the two boxes were sealable and could be connected to each other). On the first day, the mice were placed in the experimental apparatus (connected state) and allowed to move freely for 900 seconds, and the activity time of the mice in the drug-containing box was recorded and analyzed as a baseline value. On the second day, drug addiction training was conducted, and the mice were administered drugs according to the grouping requirements, and then restrained in the drug-containing box (sealed state) and trained for 30 minutes per day for a total of 7 days. After the training, on the 9th day, the mice were placed in the experimental apparatus and allowed to move freely for 900 seconds (connected state), and the activity time of the mice in the drug-containing box was recorded and analyzed. The difference between the activity time of the mice in the drug-containing box on the 9th day and the activity time of the mice in the drug-containing box on the 1st day (baseline) was used as the preference score.
[0040] 3. Experimental results As shown in Figure 3, there was a significant difference in preference scores between the normal food and drink + saline control group and the normal food and drink + morphine group, indicating that the 20 mg / kg / day morphine addiction model was successfully established. There was a significant difference in preference scores between the normal food and drink + morphine group and the low-iron content food and drink + morphine group, indicating that the low iron content in the brain due to the low-iron content food and drink has an effect on morphine addiction.
[0041] Example 4 Effect of Vadadustat on Morphine Addiction in Mice 1. Experimental materials The C57BL / 6J mice used in the present invention were purchased from Shanghai Silica Laboratory Animal Co., Ltd., and the vadadustat used in the present invention was purchased from Selleck Company.
[0042] 2. Experimental Method 2.1 Method of administering drugs to mice Thirty-six male C57BL / 6J mice (8 weeks old, weighing 22-25g) were housed in an SPF-level animal room and were randomly divided into a saline control group (10 mice), a morphine group (11 mice), a vadadustat group (10 mice), and a morphine + vadadustat group (11 mice). Mice in the saline control group were intraperitoneally injected with saline, mice in the morphine group were intraperitoneally injected with morphine (20mg / kg / day), and mice in the morphine + vadadustat group were first intraperitoneally injected with vadadustat (10mg / kg / day), and 6 hours later, they were intraperitoneally injected with morphine (20mg / kg / day). Injections were performed for 7 consecutive days.
[0043] 2.2 Mouse conditioned place preference experiment scores A conditioned place preference box (experimental apparatus) manufactured by Shanghai Jilin Software Technology Co., Ltd. was used as the behavioral training and detection apparatus. The experimental apparatus was divided into two boxes, a drug-containing box (black box) and a drug-free box (white box) (the two boxes were sealable and could be connected to each other). On the first day, the mice were placed in the experimental apparatus (connected state) and allowed to move freely for 900 seconds, and the activity time of the mice in the drug-containing box was recorded and analyzed as a baseline value. On the second day, drug addiction training was conducted, and the mice were administered drugs according to the grouping requirements, and then restrained in the drug-containing box (sealed state) and trained for 30 minutes per day for a total of 7 days. After the training, on the 9th day, the mice were placed in the experimental apparatus and allowed to move freely for 900 seconds (connected state), and the activity time of the mice in the drug-containing box was recorded and analyzed. The difference between the activity time of the mice in the drug-containing box on the 9th day and the activity time of the mice in the drug-containing box on the 1st day (baseline) was used as the preference score.
[0044] 3. Experimental results As shown in Figure 4, there was a significant difference between the preference scores of the saline control group and the morphine group, indicating that the 20 mg / kg / day morphine addiction model was successfully established. There was a significant difference between the preference scores of the morphine group and the morphine + vadadustat group, indicating that 10 mg / kg / day vadadustat had an effect on morphine addiction.
[0045] Example 5. Preventive effect of deferiprone against morphine addiction in mice. 1. Experimental materials The C57BL / 6J mice used in the present invention were purchased from Shanghai Silica Laboratory Animal Co., Ltd., and the deferiprone used in the present invention was purchased from Sigma-Aldrich Company, USA.
[0046] 2. Experimental Method 2.1 Method of administering drugs to mice Thirty-six male C57BL / 6J mice (8 weeks old, weighing 22-25g) were housed in an SPF-level animal room and were randomly divided into a saline control group (8 mice), a morphine group (7 mice), a deferiprone group (9 mice), and a morphine + deferiprone group (8 mice). Mice in the saline control group were intraperitoneally injected with saline, mice in the morphine group were intraperitoneally injected with morphine (20mg / kg / day), and mice in the morphine + deferiprone group were first administered deferiprone (13mg / mL, 1μL), and 6 hours later, they were intraperitoneally injected with morphine (20mg / kg / day). Injections were performed for 7 consecutive days.
[0047] 2.2 Mouse conditioned place preference experiment scores A conditioned place preference box (experimental apparatus) manufactured by Shanghai Jilin Software Technology Co., Ltd. was used as the behavioral training and detection apparatus. The experimental apparatus was divided into two boxes, a drug-containing box (black box) and a drug-free box (white box) (the two boxes were sealable and could be connected to each other). On the first day, the mice were placed in the experimental apparatus (connected state) and allowed to move freely for 900 seconds, and the activity time of the mice in the drug-containing box was recorded and analyzed as a baseline value. On the second day, drug addiction training was conducted, and the mice were administered drugs according to the grouping requirements, and then restrained in the drug-containing box (sealed state) and trained for 30 minutes per day for a total of 7 days. After the training, on the 9th day, the mice were placed in the experimental apparatus and allowed to move freely for 900 seconds (connected state), and the activity time of the mice in the drug-containing box was recorded and analyzed. The difference between the activity time of the mice in the drug-containing box on the 9th day and the activity time of the mice in the drug-containing box on the 1st day (baseline) was used as the preference score.
[0048] 3. Experimental results As shown in Figure 5, there was a significant difference between the preference scores of the saline control group and the morphine group, indicating that the 20 mg / kg / day morphine addiction model was successfully established. There was a significant difference between the preference scores of the morphine group and the morphine + deferiprone group, indicating that deferiprone had an effect on morphine addiction.
[0049] Obviously, the above examples are merely examples given for clarity and are not intended to limit the embodiments. Those skilled in the art can make other different types of changes or variations based on the above description. It is not possible or necessary to list all the embodiments here. And obvious changes or modifications derived therefrom still fall within the scope of protection of the present invention.
Claims
1. 2. The use of a drug that reduces the iron content in the brain in the preparation of a drug for preventing and / or treating a psychiatric disorder.
2. 2. The application of claim 1, wherein the mental illness is a mental illness caused by narcotics, drug addiction, or dependency.
3. 3. The application according to claim 2, characterized in that the narcotic drug is morphine or methamphetamine.
4. The application according to claim 1, characterized in that the drug is a hypoxia-inducible factor prolyl hydroxylase inhibitor drug or an iron chelator drug.
5. The hypoxia inducible factor prolyl hydroxylase inhibitor drug is a compound of formula I or a pharma- ceutically acceptable salt thereof, the structure of which is:
5. The application according to claim 4, characterized in that
6. The iron chelator drug is a compound represented by formula II or a pharma- ceutically acceptable salt thereof, the structure of which is:
2. The application according to claim 1, characterized in that
7. 7. The method of claim 6, wherein the pharma- ceutically acceptable salt comprises one or more of an inorganic acid salt, an organic acid salt, an alkylsulfonate, and an arylsulfonate.
8. The application of claim 1, characterized in that the drug for preventing and / or treating a mental disorder further comprises a pharma- ceutically acceptable carrier.
9. The application according to claim 8, characterized in that the carrier is one or more selected from disintegrants, diluents, lubricants, adhesives, wetting agents, flavoring agents, suspending agents, surfactants and preservatives.
10. 2. The application of claim 1, wherein the dosage form of the drug for preventing and / or treating mental disorders is a tablet, a capsule, a soft capsule, a granule, a pill, an oral liquid, an emulsion, an oral suspension, a dry extract, or an injection.
Citation Information
Patent Citations
Application of roxadustat in preparation of drug for preventing and / or treating narcotic or drug addiction
CN112755028A
Novel nitrogen-containing cyclic compounds and their uses
JP6904528B1
